RxDoctor Payments DataLook up a doctor →

Amit Narula, DO

Pulmonary Disease · Westminster, MDNPI 1497958193

Payments from drug & device makers

$226,560in general payments, 2019–2025

Across 1,311 payments — averaging $172.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$56K
  • AstraZeneca$52K
  • GSK$50K
  • Chiesi USA, Inc.$18K
  • Boehringer Ingelheim$13K
  • Jazz Pharmaceuticals Inc.$12K
  • plus $26K from 45 others

What the payments were for

  • Consulting fees$7,3284%
  • Speaking & faculty fees$142,72378%
  • Travel & lodging$3,4412%
  • Food & beverage$29,20416%
  • Education$4910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,560 in reported general payments places this provider in the 90th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$563,442
Medicare patients
1,460
Services billed
7,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate32$420,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter263$349,424
Breztri AerosphereBudesonide/Glycopyr/Formoterol139$185,805
GlassiaAlpha-1-Proteinase Inhibitor13$165,563
Stiolto RespimatTiotropium Br/Olodaterol Hcl83$76,250
Breo ElliptaFluticasone/Vilanterol107$76,238
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$51,279
Spiriva RespimatTiotropium Bromide43$48,000
Albuterol Sulfate HfaAlbuterol Sulfate460$25,934
SymbicortBudesonide/Formoterol Fumarate41$19,508
Ambrisentan13$16,169
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate50$13,517
Arnuity ElliptaFluticasone Furoate31$12,579
Ventolin HfaAlbuterol Sulfate103$11,618
EliquisApixaban17$11,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$12,903$545,136158 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$50,039$489,521450 claims
AstraZenecaBreztri Aerosphere, Symbicort$51,908$205,313180 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$338$165,56313 claims
PfizerEliquis$16$11,22717 claims
MerckDulera$90$10,88811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Westminster

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →